BenevolentAl Therapeutics Pipeline and Triage
Significant progress across all aspects of the business
since mid-2020
OOOO
Pharma
partnerships
→ Baricitinib; 38%
reduction in mortality v
SOC. Eli Lilly investment
→ AstraZeneca;
continued delivery, 1st
target selected for CKD
Pipeline Progress
→ Phase 1b for Atopic
Dermatitis progressing
well. Completion by
mid-2022
→IND-enabling studies
started for novel
Ulcerative Colitis asset
(PDE10)
Platform
Enhancements
→ Mechanism mapping
to better represent
disease
→ Improved capacity to
ingest human patient
level data and genetics
at scale
Business Model
→ Ambition to take
assets through to
commercialisation
ourselves including,
PDE10 for UC
People
→ Building a world-class
Board (Dr. Francois
Nader, Dr. John Orloff,
Sir Nigel Shadbolt)
→ Investing in people to
support a scaling
pipeline (>80 recruited
in last year)
Al
Benevolent 74View entire presentation